Akebia Therapeutics
A fully integrated biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease.
The US company's lead product candidate is vadadustat. It is part of a new class of investigational agents called oral hypoxia-inducible factor prolyl hydroxylase inhibitors.
Within Japan, Vafseo (vadadustat) is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
Latest Akebia Therapeutics News & Features
28 March 2024
18 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze